On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a ...

The KSE-100 index of Pakistan Stock Exchange (PSX) lost on Tuesday more than 400 points, weighed down by institutional profit ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...

Harvey Jones thought he was getting a bargain when he snapped up these too much-loved FTSE 100 dividend growth stocks. Now they're getting on his nerves. The post These 2 former stock market darlings ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50 ... corporate insider sentiment is positive on ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...

JPMorgan lowered the firm’s price target on GSK (GSK) to 1,440 GBp from 1,550 GBp and keeps an Underweight rating on the shares. TipRanks is the most comprehensive data set of sell side analysts ...